O. Silva

发表

A Phase II trial of split, low-dose docetaxel and low-dose capecitabine: a tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-negative metastatic breast cancer.

J. Slingerland, G. Lopes, I. Reis, 2008, Clinical breast cancer.

Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II–IIIc breast cancer

L. Koniaris, M. Jordá, J. Slingerland, 2012, Breast Cancer Research and Treatment.

Improved clinical outcomes associated with vitamin D supplementation during adjuvant chemotherapy in patients with HER2+ nonmetastatic breast cancer.

S. Glück, T. Koru-Sengul, A. Montero, 2015, Clinical breast cancer.

A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere

H. Soares, Mark R. Green, G. Lopes, 2014, Cancer Chemotherapy and Pharmacology.

A myxoid chondrosarcoma associated with an anti-Hu-positive paraneoplastic encephalomyelitis

C. Singer, J. Vredenburgh, P. Robinson, 2010, Journal of Neuro-Oncology.

Paclitaxel albumin-bound particles (abraxane) in combination with bevacizumab with or without gemcitabine: early experience at the University of Miami/Braman Family Breast Cancer Institute.

G. Lopes, S. Gluck, O. Silva, 2007, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Neoadjuvant platinum-based chemotherapy (CT) for triple-negative locally advanced breast cancer (LABC): Retrospective analysis of 125 patients.

M. Pegram, J. Leone, C. Welsh, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Small-cell cancer of the breast: what is the optimal treatment? A report and review of outcomes.

H. Gómez, J. Cortés, C. R. Rocha Lima, 2012, Clinical breast cancer.

Patient with Metastatic Breast Cancer Achieves Stable Disease for 5 Years on Graviola and Xeloda after Progressing on Multiple Lines of Therapy

D. Hansra, E. Ahn, Ashwin Mehta, 2014 .

Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer.

D. Slamon, C. Gomez-Fernandez, M. Pegram, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non-small-cell lung cancer (NSCLC).

K. Hamilton-Nelson, E. Roman, L. Raez, 2006, Lung cancer.

Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma.

P. Blondeel, H. Depypere, V. Cocquyt, 2003, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Primary ectopic breast cancer presenting as a vulvar mass.

M. Jordá, G. Lopes, S. Glück, 2006, Clinical breast cancer.

Weekly docetaxel/carboplatin as primary systemic therapy for HER2-negative locally advanced breast cancer.

I. Reis, C. Welsh, J. Hurley, 2005, Clinical breast cancer.

Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

J. Slingerland, G. Lopes, I. Reis, 2010, Breast Cancer Research and Treatment.

Sunitinib-induced microangiopathic hemolytic anemia with fatal outcome.

J. Merchan, A. Stefanovic, T. Talebi, 2012, American journal of therapeutics.

High rate of axillary node clearence with neoadjuvant Herceptin, Taxotere, and Cisplatin in locally advanced advanced and inflammatory breast cancer

C. Gomez-Fernandez, I. Reis, J. Hurley, 2001 .